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Introduction
Fostriecin and cytostatin are structurally related phosphate monoesters produced by Streptromyces (S. pulveraceus and S. MJ654-Nf4, respectively) that display cytotoxicity and antitumor activity [for review see; (Lewy et al., 2002) ]. Cytostatin has cytotoxic activity towards melanoma and leukemia cell lines and has been shown to inhibit lung tumor metastasis (Masuda et al., 1995; Kawada et al., 1999) . The antitumor activity of fostriecin (also called NSC 339638, or PD 110, 161) has been evaluated extensively [for review see; (de Jong et al., 1997; Lewy et al., 2002; Honkanen, 2005) ]. It demonstrates marked cytotoxicity against many cancer cell lines and potent antitumor activity in animals [for review see (de Jong et al., 1997; Lewy et al., 2002; Honkanen, 2005) ]. To evaluate its potential for use as an anti-tumor agent in humans, fostriecin entered NCI-sponsored clinical trials (Le et al., 2004) .
Although limited, the data obtained from the Phase 1 trials suggests that plasma levels of fostriecin shown to have antitumor activity in animals can be achieved in humans (Leopold et al., 1984; Susick et al., 1990; Le et al., 2004) . Unfortunately, the trials were discontinued before the MTD (maximum tolerated dose) was established, when concerns related to the storage stability of the naturally produced material surfaced (Le et al., 2004) .
The biological actions of fostriecin were initially ascribed to its ability to inhibit topoisomerase II; however, its cell cycle effects and potency are inconsistent with this target of action [for review see; (Lewy et al., 2002; Honkanen, 2005) ]. Subsequently, fostriecin (Walsh et al., 1997; Buck et al., 2003) , cytostatin (Bialy and Waldmann, 2004; Lawhorn et al., 2006) and structurally related natural products [phospholine, leustroducsin and phoslactomycins (Usui et al., 1999; Kawada et al., 2003) ; Figure 1 ] have all been shown to inhibit a subset of PPP-family serine/threonine protein phosphatases. Fostriecin acts as a potent inhibitor of PP2A/PP4 (IC 50 0.2-4 nM) and a weak inhibitor of PP1 and PP5 (PP2A/PP4 vs PP1/PP5 selectivity >10 4 ) (Walsh et al., 1997; Buck et al., 2003) . Cytostatin is also a potent and selective inhibitor of PP2A (PP2A IC 50 =20-400 nM; PP2A vs PP1/PP5 > 10 3 ) (Bialy and Waldmann, 2004; Lawhorn et al., 2006) . Phospholine, leustroducsin H, and phoslactomycins are weaker inhibitors of PP2A (Usui et al., 1999; Kawada et al., 2003) and have not been examined using other phosphatases.
This article has not been copyedited and formatted. The final version may differ from this version. Following the first total synthesis of fostriecin (Boger et al., 2001) , at least nine total or formal syntheses have been reported (Chavez and Jacobsen, 2001; Esumi et al., 2002; Reddy and Falck, 2002; Miyashita et al., 2003; Maki et al., 2005; Trost et al., 2005) . The total synthesis of cytostatin (Bialy and Waldmann, 2004; Lawhorn et al., 2006; Jung et al., 2008) and cytostatin analogs (Lawhorn et al., 2006; Jung et al., 2008) have also been reported. These studies have sparked renewed interest in the potential for development of more stable derivatives that may have utility as novel anti-tumor drugs.
In efforts to identify the features of fostriecin-family compounds required for its potent and selective inhibition of PP2A, we have reported the synthesis of structural derivatives of fostriecin (Buck JPET #155630   6 fostriecin (Buck et al., 2003) and cytostatin (Lawhorn et al., 2006) are considered along with structural studies of PP2A (Buck et al., 2003; Xing et al., 2006) , we predicted that the unsaturated lactone reacts with a cysteine near the active site of PP2A (Buck et al., 2003) and a hydrogen bond occurs between the C11-hydroxyl and arg 214 , which is a conserved binding feature of the non-selective PP1 pharmacophore (Colby and Chamberlin, 2006) . Still, comparison of PP1, PP2A, and PP5, reveal sequence and conformational differences near the active site, suggesting the feasibility of developing type-specific inhibitors. Notably, differences occur in the β12-β13 loop, a region immediately adjacent to the active site and known to participate in okadaic acid and microcystin mediated inhibition of PP1 (Goldberg et al., 1995) and PP2A (Xing et al., 2006) . Here, we performed site-directed mutagenesis of PP1c and PP5c, altering domains predicted to be important for inhibitor binding in PP2Ac. Then head-to-head doseresponse studies were conducted with PP1c, PP2Ac, PP5c and chimeras (PP1/PP2A and PP5/PP2A), testing key compounds for inhibitory activity.
Methods
Synthesis and Characterization of Inhibitors.
The synthesis and structural characterization of fostriecin, cytostatin and structural analogues (compounds 1, 2, 6-15) has been described (Boger et al., 2001; Buck et al., 2003; Lawhorn et al., 2006) .
Preparation of Phosphohistone Substrate and Determination of Phosphatase Activity.
Phosphohistone with a specific activity of >4.5 X10 6 dpm/ nmole of incorporated phosphate, was prepared by the phosphorylation of bovine brain histone with cAMP-dependent protein kinase (PKA) from rabbit muscle in the presence of [ 32 P]ATP. Histone (type-2AS) was phosphorylated with PKA in a reaction containing 10 mg/ml histone, 2 mg/ml PKA, 6 mCi/ml [γ 32 P]ATP (200 mM ATP), 0.4 mM cAMP, 40 mM PIPES pH 6.8 (at 37 o C), 7 mM MgCl 2 , 0.1 mM EDTA, and 5 mM DTT as described previously (Honkanen et al., 1990; Walsh et al., 1997; Swingle et al., 2007) .
Protein phosphatase activity against phosphohistone was measured by the quantification of [ 32 P] liberated from phosphohistone, using established protocols (Honkanen et al., 1990; Swingle et al., 2007) .
This article has not been copyedited and formatted. The final version may differ from this version. Briefly, dephosphorylation reactions were conducted for 10 minutes at 30 o C. For all reactions the dephosphorylation of substrate was kept to less than 5% of the total phosphorylated substrate, and the reactions were linear with respect to enzyme concentration and time. For inhibition studies, compounds were added to the enzymes 10 minutes prior to the initiation of the reaction by the addition of substrate.
In the literature, the reported strength of PP2A inhibition for fostriecin and cytostatin varies considerably (e.g. IC 50 values range from 0.2 nM to 40 nM for fostriecin). This likely reflects differences in the amount of enzyme used in the assay, the choice of substrate, and/or handling/stability issues that are not widely appreciated [e.g. the inhibitory activity of fostriecin can be greatly reduced by even a brief exposure to weak acid (pH <5.5) or base pH >7.5 (Swingle et al., 2007) ]. Therefore, when comparing the inhibitory actions of an analogue series, it is important to consider stability issues and conduct side-byside measurements using similar amounts of protein with the same substrate. All of the phosphatases employed were highly purified, demonstrating a single band upon SDS-PAGE and Coomassie staining.
For studies employing high affinity inhibitors, it is also important to ensure the free inhibitor concentration in the assay is not reduced significantly through binding and sequestration of inhibitors by the PPase in the assay (i.e. "titration").
Here, a Microcystin-titration assay [described in detail previously; (Swingle et al., 2007) ] was used to accurately determine the amount of PPase used in the assays.
Mutagenesis, Cloning Expression and Purification of PP1 and PP5. Regions within the β12-β13 loop of human PP1c-alpha and PP5c were mutated at the residues indicated, replacing the amino acids endogenous to PP1 or PP5 with the corresponding residues contained in PP2Ac (267 YRCG 270, and combinations there of) using the Stratagene Quick Change Site-Directed Mutagenesis kit. All resulting products were sequenced to verify the fidelity of the mutations and the integrity of the expression constructs. For expression, PP1c, PP5c and the mutants produced (PP1-YRCG, PP5-YRCG)
were cloned into a modified pMal-c2E expression vector (Swingle et al., 2004 using a French Press, followed by centrifugation at 45,000 g for 1 hour at 4º C. The proteins were purified using a nickel-iminodiacetate column as described previously (Swingle et al., 2004) . The purified fusion proteins were then digested with TEV protease, and free PP5c was further purified via anion-exchange chromatography using Q-Sepharose resin for PP5 as described previously (Swingle et al., 2004) . Further purification of PP1 was achieved using a 5 ml HiTrap Heparin column (Amersham Biosciences) equilibrated with Buffer A. PP1c was eluted using a 1-100% linear gradient of Buffer B (20 mM Tris pH 7.4, 10 µM EDTA, 0.001% Brij-25, 1 mM MnCl 2 , 0.007% β-mercaptoethanol, 20% glycerol, 1 M NaCl).
Changes made to the β12-β13 loop did not significantly affect column retention. Active fractions were identified by activity against p-nitrophenylphosphate (pNPP, Sigma). Fractions containing the highest pNPP activity were pooled and stored at -80ºC. The final preparations were > 90% pure as judged by SDS-PAGE. Native PP2Ac, was purified as described previously (Walsh et al., 1997) .
Computer Modeling of PP1, PP2A, PP5 and Inhibitors. For inhibitor docking studies, Autodock 3.05 (Morris et al., 1998) was modified to use a particle swarm optimization algorithm (Kennedy and Eberhart, 1995) as the search algorithm according to methods of Chen et al. (Chen et al., 2007) . Coordinate files for fostriecin were generated with ghemical (Hassinen and Peräkylä, 2001) . ADT (http://autodock.scripps.edu/ resources/adt/index_html) was used as a graphical user interface to the programs in the autodock suite (i.e. autotors, addsol, atmtobnd, protonate, autogrid3, autodock3 and makelaunch) and for analysis of docking results.
Atomic coordinates for the protein phosphatase 2A catalytic subunit (Xing et al., 2006) were obtained from the RCSB protein data bank (PDB: 2IE4). All water molecules and okadaic acid were removed and polar hydrogen atoms were added. Kollman united atom template charges were assigned with ADT. The solvation parameters (Stouten et al., 1993) were calculated with addsol. The prepared 9 rather large grid (80x62x68 points with 0.375A spacing) was defined for the calculation of maps, which encompassed the dinuclear catalytic center of PP2Ac as well as the "hydrophobic" and "acidic" grooves on the protein's surface.
All atom models of fostriecin built with ghemical and optimized with the Tripos 5.2 force field.
Gasteiger charges (Gasteiger J., 1980) were assigned to all atoms. At physiological pH, the ligand phosphoryl groups are likely to be predominately dianionic. Thus, for purposes of docking, phosphoryl groups were built completely unprotonated. All non-polar hydrogens were merged within the united atom approach with autotors, which was also used to define which bonds were treated as freely rotatable during the docking run. Ligands were saved in the PDBQ format required by autodock3. In the united atom approach, bonds to terminal methyl groups are not freely rotatable. However, hydroxyl groups are treated as rotatable as the hydrogen is polar. Due to their partial double-bond character, bonds in the triene tail were set as non-rotatable. The modified version of AutoDock described above was used to evaluate and optimize ligand binding energies over the conformational search space using a particle swarm optimization/local search hybrid algorithm. Population size was set to 50 and the number of energy evaluations was set to 5 million.
Results
Inhibition of PP1, PP2A and PP5 Phosphatase Activity. Fostriecin, cytostatin, and a series of 10 structural analogs were synthesized using previously published methods (Buck et al., 2003; Lawhorn et al., 2006) . In side-by-side measurements using equal amounts of enzymes and [ Swingle et al., 2004) and mutational analysis (Zhang et al., 1996) indicate that both PP1 and PP5 share a common catalytic mechanism with PP2A. Indeed PP1, PP2A, PP2B, and PP5 all contain a common catalytic pocket consisting of 10 conserved amino acids (Figure 3 ). Computer models predicted that fostriecin binds to a unique region of PP2A contained in the β12-β13 loop, and mutational analysis of PP1 revealed considerable insight into the binding of natural inhibitors (Zhang et al., 1994; Zhang et al., 1996) . Therefore, we performed site-directed mutagenesis, replacing endogenous amino acids in the β12-β13 loop of PP1 and PP5 with the corresponding amino acids (YRCG) in PP2A. Then, in side-by-side dose-response studies, we tested the sensitivity of the PP1(YRCG)-and PP5(YRCG)-chimeras to fostriecin, cytostatin and key analogs. In PP1, conversion to YRCG resulted in a ~600 fold increase in sensitivity to fostriecin ( Figure 4A ; IC 50 = 0.09 +/-0.02 vs ~72 +/-11 μM). With PP5, a ~200 fold increase in sensitivity was produced by as similar (YRCG) mutation ( Figure 4B ; IC 50 = 0.3 +/-0.08 vs 60.5 +/ 0.6 μM). Mutation of a single residue in PP5 (PP5 M to C) increased sensitivity to fostriecin by ~50 fold (IC 50 =1.2 +/-0.5 μM). PP1(YRCG) and PP5(YRCG) were also sensitive to cytostatin (IC 50 = 17 +/-3.2 and 34 +/-6.1 μM, respectively), which has little effect on native PP1 or PP5 (IC 50 >100 μM).
Compounds, in which the lactone ring is deleted or disrupted (9) and (10), demonstrated no detectable increase in inhibitory activity against PP1(YRCG) or PP5(YRCG). In contrast, compounds retaining the phosphate monoester and unsaturated lactone (i.e. 1, 2, 11-15) demonstrated increased potency against the chimeras (Table 1) .
Discussion.
To date, >10 natural compounds have been identified that share a distinctive phosphate monoester and α,β-unsaturated δ-lactone structural units with fostriecin (Figure 1 ). Fostriecin and cytostatin, which both act as potent inhibitors of PP2A (Walsh et al., 1997; Buck et al., 2003; Lawhorn et al., 2006 ) also share a (Z,Z,E)-triene. The total synthesis of fostriecin (1) (Boger et al., 2001; Chavez and Jacobsen, 2001) , cytostatin (2) (Lawhorn et al., 2006) and more recently several key analogs (compounds 6-15) (Buck et al., 2003; Lawhorn et al., 2006) , have enabled further structure activity relationship studies 11 to explore the inhibitory activity of the fostriecin family of inhibitors. As known from previous studies (Buck et al., 2003; Lawhorn et al., 2006) and shown in Figure 2A , fostriecin (1; IC 50 =1.4 nM) is an ~20
fold more potent inhibitor of PP2A than cytostatin (2; IC 50 =29.0 nM). At much higher concentrations, fostriecin is essentially an equipotent inhibitor of PP5 and PP1 (IC 50 ~60 μM), and cytostatin has little effect on PP1 or PP5 (IC 50 >100 μM). Thus, the selectivity of (1) and (2) for PP2A is substantial (PP2A/PP1-PP5 >10 4 ). The known (Buck et al., 2003; Lawhorn et al., 2006) importance of the C9 phosphate for both (1) and (2) is illustrated in Figure 2A , where dephosphofostriecin (7) and dephosphocytostatin (8) have minimal inhibitory activity against PP2A (IC 50 >100 μM). When the phosphate is converted into a phosphodiester (6), inhibitory activity against PP2A is reduced ~ 10 3 fold (IC 50 3.2 +/-1.1 μM). Both dephosphocompounds also have reduced inhibitory activity against PP1 and PP5 (not shown) suggesting the phosphate interacts with conserved catalytic residues. However, (1) and (2) also differ at C4 and C17. In addition, derivatives in which the entire lactone (10) or the entire (Z,Z,E)-triene (11) are deleted still strongly inhibit PP2A, while having little effect on PP1 or PP5 ( Figure   2C and D). We interpret this to indicate that both the lactone and the (Z,Z,E)-triene contribute to selectivity.
Computer models of interactions between (1) or (2) with PPP-family phosphatases suggest that the phosphate and the common C11-hydroxyl interact with regions conserved in PP1, PP2A and PP5 (i.e.
the catalytic metals and conserved active site residues that coordinate the metals and/or position the incoming substrate for nucleophilic attack) which is consistent with the inhibition data presented above.
The models also predict that the unsaturated lactone contributes to the strong inhibitory actions of PP2A, due to an electrophilic interaction with a cysteine (cys 269 ) contained in the β12-β13 loop of PP2A that is not present in PP1 and PP5 ( Figure 3C ). This prediction is supported by the decreased PP2A inhibitory activity of (9), in which the electrophilic nature of C3 is absent, and (10), in which the entire lactone moiety is deleted ( Figure 2C and D) . To further test this hypothesis, we performed site-directed mutagenesis, replacing endogenous amino acids in the β12-β13 loop of PP1 and PP5 with the 12 corresponding amino acids in PP2A. For both PP1 and PP5, the region needed for strong inhibition was mapped to 4 amino acids immediately adjacent to the active site tyrosine (Tyr 265 ). In PP1, conversion from GEFD to YRCG (the sequence contained in PP2A) resulted in a ~600 fold increase in sensitivity to fostriecin ( Figure 4A ). With PP5, a ~200 fold increase in sensitivity was produced by as similar (DQMG to YRCG) mutation ( Figure 4B ). PP1-and PP5-YRCG mutants were also sensitive to cytostatin (IC 50 = 17 +/-3.2 and 34 +/-6.1 μM, respectively), which has little effect on native PP1 or PP5 (IC 50 >100 μM).
Compounds, in which the lactone ring is deleted or disrupted (9) and (10), demonstrated no detectable increase in inhibitory activity against PP1(YRCG) or PP5(YRCG). In addition, (11), which lacks the (Z,Z,E)-triene, demonstrated similar strength in the inhibition of PP2A, PP1(YRCG) and PP5(YRCG) while having minimal activity against native PP1 or PP5. Together these studies support the critical role of an interaction between C3 and cys 269 in the β12-β13 loop of PP2A. The critical role of cys 269 in fostriecin sensitivity is also supported by our previous SAR studies using additional derivatives of fostriecin (Buck et al., 2003) and studies in yeast, in which a 10-fold decrease in sensitivity to fostriecin induced by random mutagenesis was associated with a homologous C269S mutation (Evans and Simon, 2001 ).
In addition to the lactone, (1), (2) and (11) share in common a C11-alcohol, and C10 of (2) and (11) contains a methyl group not contained in (1), (9) or (10). Thus, four C10/C11 cytostatin diastereomers [(12), (13), (14) and (15)] were tested on PP1, PP2A and PP1 (YRCG). As we reported previously (Buck et al., 2003; Lawhorn et al., 2006) compared to the natural compound (2), each of these cytostatin diastereomers were less potent inhibitors of PP2A. The C11 epimer (12), in which only the stereochemistry of the alcohols is inverted, the C10-epimer (13), in which only the stereochemistry of the methyl group is inverted, and the (10R,11R)-diastereomer (14), in which both the C11-methyl group and the C11-alcohol are inverted, all proved to be stronger inhibitors of PP1 (YRCG) than PP1 (Table 1 ). All three cytostatin epimers also demonstrated similar strength against PP1(YRCG) and PP2A. In addition, Together, these observations provide compelling data supporting the concept that much of the selectivity for PP2A observed with fostriecin-family inhibitors is indeed derived from the interaction between C3 of the inhibitors and the β12-β13 loop in PP2A. Nonetheless, because (9) and (10) are still highly selective for PP2A (Figure 2 ), additional selectivity is likely derived from the (Z,Z,E)-triene.
To gain additional insight into the interactions that aid the selective inhibition of PP2A, bound conformations of (1) were generated via molecular docking with a modified version of autodock 3.05 (see cutoff. These clusters can be thought of as representing a binding mode plus snapshots of the associated relative internal motions of the receptor-ligand complex (Ruvinsky and Kozintsev, 2005) .
The docking of fostriecin to PP2Ac results in 33 non-overlapping clusters (8 with more than 2 members). The 3 clusters with the lowest estimated binding energy (ranked according to the best member)
show fostriecin bound (for a representative structure; see Figure 5 ) with the phosphate moiety coordinated to the active site metals and forming hydrogen bonds with highly conserved active site residues (asn 117 , his 118 , arg 214 , and tyr 265 ), the (Z,Z,E)-triene placed in the acidic groove, and the unsaturated lactone ring nestled in a pocket formed by the highly conserved arg 89 and 4 residues in the β12-13 loop: tyr 265 , cys 266 , arg 268 , and cys 269 . Importantly, this conformation places the gamma-sulfur of cys 269 3.6 Å away from the electrophilic C3, suggesting that binding to PP2A pre-positions the lactone ring for nucleophilic attack.
Two of the residues in the lactone binding pocket, arg 268 (1) fostriecin (filled squares), (2) cytostatin (filled circles), (7) dephosphofostriecin (open squares), and (8) dephosphocytostatin (open circles) on the activity of purified PP2Ac. B) Effect of (10) (filled square) and (11) (filled circle) on the activity of PP2Ac. C)
Comparison of the inhibitory effect of (10) on the activity of PP2Ac (filled square), PP1 (filled circle) and PP5 (filled diamond). D) Comparison of the inhibitory effect of (11) and PP5, respectively. PP1-α (red), PP5 (blue), PP2B (yellow), and PP2A (black) are from pdb codes 1JK7, 1S95, 1TCO, and 2IE4, respectively. Superpositions were performed with STRAP (http://www.charite.de/bioinf/strap/) B) Detailed representation of key substrate contacts in the catalytic site shared by PP1, PP2A, and PP5. The active site residues were positioned using the data from the structure of PP5c (PDB 1S95) with PP1 and PP2A numbering shown in blue. Through hydrogen bonds (yellow dotted lines lines) four conserved amino acids (R 96,89,275 , N 124,117,303 , H 125,118,304 and R 221,214,400 ) help position the substrate phosphate ion for nucleophilic attack. The other six function as metal-coordinating residues (coordination bonds shown as red solid lines) which position and help activate a terminally ligated hydroxide that acts as a nucleophile in the catalytic reaction (Swingle et al., 2004) . These ten amino acids are positioned by the compact alpha/beta fold comprised of 11 alpha helices and 14 beta strands common to PP1, PP2A and PP5. The metal activated water is shown as a green sphere (W1) in a near nucleophilic-attack configuration of the substrate phosphate (P). C) Surface filled structures illustrating the catalytic pocket and β12-β13 region of PP1c, PP2Ac and PP5c. Surface fill models of PP1c, PP2Ac and PP5c were generated from the PDB codes (as above) using PyMOL Cytostatin (2) 0.029 +/-0.007 >100 17 +/-3.2 >100 34 +/-6.1 7 >100 >100 >100 >100 >100 8 >100 >100 >100 >100 >100 9 2.1 +/-0.6 >100 >100 >100 >100 10 0.1 +/-0.02 ~100* ~100* >100 >100 expressed in E. coli. as described previously (Honkanen et al., 1990; Walsh et al., 1997; Swingle et al., 2004; Swingle et al., 2007) . Assays were conducted side-by-side using similar amount of enzyme and proteins used here demonstrated similar activity (Swingle et al., 2004; Swingle et al., 2007) and sensitivity to fostriecin, cytostatin, and other known inhibitors (i.e. okadaic acid, cantharidin, calyculin A, and microcystin-LR (Honkanen et al., 1990; Swingle et al., 2007) ). The data shown represents the mean +/-SD, n>5. * Enzyme inhibition at 100 μM = 44-55%.
This article has not been copyedited and formatted. The final version may differ from this version. 
